Signal from the log
Lys Therapeutics
25 M€ · Undisclosed · France · Biotech
Biotech lyonnaise qui développe des anticorps monoclonaux réparant la barrière hémato-encéphalique, dont LYS241, contre la maladie de Parkinson et l'accident vasculaire cérébral. Attention à la composition du tour : il mêle des investisseurs privés, Bpifrance, France 2030 et une dotation de 5 M$ de la fondation Michael J. Fox, donc une part non dilutive que le communiqué ne détaille pas.
Spotted
Announced on , logged by the watch of 12 August 2026.
- Operation
- Funding round
- Announced amount
- 25 M€
- Stage
- Undisclosed
- Country
- France
- Sector
- Biotech
What the log says
Editorial note, in French
Repérée par la collecte. Personne ne l'a encore instruite.
The investors
Led by Bpifrance , France 2030 , Michael J. Fox Foundation
Provenance
Source longevity
Logged on 12 August 2026
Description Written in French during the watch run. Written during the watch run, after reading the issuer's press release or the source article.
Verification Amounts and fund names were double checked against the issuer's press release or an official filing.
What this status means
Spotted The collection saw this operation and logged it. Nobody has processed it yet, so what is shown is still an automatic reading of the source headline.
The rule A signal is never removed from the log. A round set aside stays readable with its reason, because a collection you cannot reread is a collection you cannot correct.